Technology Is Reshaping Sleep Apnea Treatment

For decades, cumbersome CPAP machines have been the primary way to help people with sleep apnea. A range of new options has ...
The Advocate

Up next: Belaire High in line to change start times, more Baton Rouge schools to follow

Belaire High, home to almost 600 students, would start school 80 minutes later than at present. It would follow in the ...

Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes

Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 programMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex ...

Sleep Awareness Week: How To Create A Stylish And Healthy Bedroom

Your bedroom’s design, sleep habits, indoor allergens and pollutants in the bedroom, and several other factors can determine how well you sleep.

Incannex Healthcare: Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, ...
The Manila Times

Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 million ...
Asianet Newsable on MSN

IXHL stock rips to best day in 5 months: Nasdaq compliance back in sight as FDA catalyst for sleep apnea drug looms

Investors are watching the company’s Nasdaq compliance timeline after it received a 180-day extension until April 20 to meet ...

Buy The Fear: I Am Loading Up On 2 Big Income Machines

Market fears around private credit and banking regulations have created mispricing in certain assets that are fundamentally ...
Morning Overview on MSN

Repurposed drug cut sleep apnea events by up to 50% in trial

A repurposed epilepsy drug called sultiame cut breathing interruptions during sleep by up to 50% in adults with moderate-to-severe obstructive sleep apnea, according to results from a major European ...

Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial ...

The FDA assigned a PDUFA target action date of December 22, 2026 - - The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction ...

Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript

The Citizens Life Sciences Conference 2026 March 10, 2026 4:00 PM EDTCompany ParticipantsMark Jacobson - Chief ...
TechCrunch

Eight Sleep raises $50M at $1.5B valuation

Sleep tech company Eight Sleep today said that it has raised $50 million in a strategic round led by Tether Investments at a valuation of $1.5 billion. This new round comes after the startup closed a ...